| Literature DB >> 31665153 |
John M Humphrey1, Violet Naanyu2,3, Katherine R MacDonald4, Kara Wools-Kaloustian1, Gregory D Zimet4.
Abstract
Discrete choice experiments (DCE), conjoint analysis (CA), and best-worst scaling (BWS) are quantitative techniques for estimating consumer preferences for products or services. These methods are increasingly used in healthcare research, but their applications within the field of HIV research have not yet been described. The objective of this scoping review was to systematically map the extent and nature of published DCE, CA, and BWS studies in the field of HIV and identify priority areas where these methods can be used in the future. Online databases were searched to identify published HIV-related DCE, CA and BWS studies in any country and year as the primary outcome. After screening 1,496 citations, 57 studies were identified that were conducted in 26 countries from 2000-2017. The frequency of published studies increased over time and covered HIV themes relating to prevention (n = 25), counselling and testing (n = 10), service delivery (n = 10), and antiretroviral therapy (n = 12). Most studies were DCEs (63%) followed by CA (37%) and BWS (4%). The median [IQR] sample size was 288 [138-496] participants, and 74% of studies used primary qualitative data to develop attributes. Only 30% of studies were conducted in sub-Saharan Africa where the burden of HIV is highest. Moreover, few studies surveyed key populations including men who have sex with men, transgender people, pregnant and postpartum women, adolescents, and people who inject drugs. These populations represent priorities for future stated-preference research. This scoping review can help researchers, policy makers, program implementers, and health economists to better understand the various applications of stated-preference research methods in the field of HIV.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31665153 PMCID: PMC6821403 DOI: 10.1371/journal.pone.0224566
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Summary of discrete choice experiment and conjoint analysis methods.
Fig 2Summary of best-worst scaling methods.
Fig 3Flow diagram of article selection.
Summary of HIV research studies using discrete choice, conjoint analysis and best-worst scaling methods (n = 57).
| Author, Ref. | Country | Study Year(s) | Study Objective | Study Type | Population | Probability Sampling | Sample Size | Method of Attribute & Level Selection | Number of Attributes | Number of Choice sets |
|---|---|---|---|---|---|---|---|---|---|---|
| Christofides [ | South Africa | 2003–04 | To describe which aspects of health services after rape are most valued by women and the trade-offs women would make between different aspects of service delivery. | DCE | Women without HIV | n/s | 319 | FG, KII, | 5 | 16 |
| Scalone [ | United Kingdom, USA | 2004 | To investigate preferences and willingness to pay for medical treatments for genital herpes. | DCE | Adults with genital herpes | Yes | 154 | LR | 6 | 16 |
| Mays [ | USA | 2004 | To examine nurses’ willingness to recommend STI vaccines to parents of adolescent patients. | CA | Nurses | No | 224 | LR | 4 | 13 |
| Terris-Prestholt [ | South Africa | 2005 | To understand the relative strength of women’s preferences for new HIV prevention product characteristics. | DCE | Women without HIV | No | 1,017 | FG, KII | 5 | 6 |
| Holt [ | USA | 2006 | To assess preferences for various possible microbicide characteristics. | CA | Adults at risk of HIV | No | 335 | FG | 6 | 15 |
| Newman [ | USA | 2006–07 | To assess HIV vaccine acceptability. | CA | Adults at risk of HIV | Yes | 1,164 | KII, FG, LR | 7 | 9 |
| Lee [ | USA | 2008 | To assess preferences for hypothetical HIV vaccines. | CA | Adults without HIV | No | 27 | AT, FG, KII, LR | 7 | 8 |
| Tanner [ | USA | 2008 | To assess preferences for microbicide characteristics. | CA | Adolescents and young women | No | 405 | AT, FG, KII | 4 | 8 |
| Reese [ | USA | 2008–09 | To evaluate patients’ preferences for accepting a kidney from a donor with an increased risk of having a blood-borne viral infection such as HIV. | DCE | Adults kidney transplant candidates without HIV | No | 175 | KII, FG, LR | 3 | 12 |
| Cameron [ | Thailand | 2008–09 | To estimate the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. | CA, BWS, DCE | Adults without HIV | No | 324 | FG, LR | 7 | 8 |
| Newman [ | Thailand | 2008–09 | To assess HIV vaccine acceptability, the impact of vaccine attributes on acceptability, and risk compensation intentions. | CA | MSM and transgender women | No | 255 | KII, LR | 7 | 8 |
| Eisingerich [ | Peru, Ukraine, Kenya, Uganda, Botswana, South Africa, India | 2010–11 | To explore attitudes and preferences towards attributes of PrEP programs and medications, and the future acceptability of PrEP. | DCE | Female sex workers, MSM, serodiscordant couples | No | 1,824 | KII | 5 | 10 |
| Wheelock [ | Thailand | 2011 | To examine the attitudes, preferences and acceptability of PrEP. | DCE | MSM without HIV | No | 260 | KII | 5 | 10 |
| Galea [ | Peru | 2011 | To examine PrEP acceptability. | CA | Female sex workers, MSM, transgender persons | No | 45 | KII, LR | 7 | 8 |
| Kinsler [ | Brazil, Peru | 2012 | To explore the acceptability hypothetical rectal microbicides. | CA | MSM | No | 128 | FG, KII, LR | 7 | 8 |
| Lee [ | USA | 2012 | To assess future HIV vaccine acceptability. | CA | Adults at risk of HIV | No | 143 | FG, KII | 7 | 8 |
| Bridges [ | South Africa | 2012 | To value design characteristics of potential community-based male circumcision services to prevent HIV transmission. | DCE | Community members | Yes | 645 | KII | 11 | 6 |
| Newman [ | Thailand | 2013 | To assess preferences and acceptability of hypothetical rectal microbicides. | DCE | MSM, transgender women, sex workers | No | 408 | AT, FG, LR | 5 | 8 |
| Tang [ | Peru | 2014 | To understand the acceptability of hypothetical rectal microbicides. | CA | MSM | No | 1,008 | LR | 6 | 8 |
| Quaife [ | South Africa | 2015 | To explore preferences regarding HIV prevention products, quantify the importance of product attributes, and predict uptake of products. | DCE | Adults, adolescent girls, Female sex workers | Yes | 609 | FG, LR | 6 | 10 |
| Shrestha [ | USA | 2016 | To investigate PrEP acceptability and preferences for PrEP delivery. | CA | People who use drugs | No | 400 | AT, FG, KII, LR | 6 | 8 |
| Dubov [ | Ukraine | 2016 | To determine preferences for PrEP delivery. | DCE | MSM | No | 1,184 | KII, LR | 5 | 14 |
| Primrose [ | USA | 2016 | To better understand what sexually-active women want in a vaginal microbicide to protect against HIV transmission. | CA | Women without HIV | No | 302 | n/s | 7 | 49 |
| Alcaide [ | Zambia | 2016 | To identify the importance of factors underlying the decision to engage in intravaginal practices that may increase the risk of HIV transmission. | CA | Women with HIV | No | 128 | FG, KII | 3 | 9 |
| Rodriguez [ | Zambia | 2017 | To explore the importance of factors underlying women’s decisions to engage in intravaginal practices that may increase HIV acquisition risk. | CA | Women without HIV | No | 84 | FG, KII | 3 | 9 |
| Phillips [ | USA | 1999–2002 | To examine preferences for HIV test methods. | DCE | Adults obtaining HIV tests | No | 365 | FG, LR, KII, pilot survey | 6 | 11 |
| Llewellyn [ | United Kingdom | 2011 | To assess preferences for sexually transmitted infection testing services. | DCE | University students | No | 233 | FG, KII, LR | 6 | 16 |
| Lee [ | USA | 2011 | To examine MSM preferences for HIV testing scenarios that influence the willingness to test for HIV. | CA | MSM without HIV | n/s | 75 | LR | 7 | 8 |
| Ostermann [ | Tanzania | 2012–14 | To compare HIV testing preferences of female bar workers and male Kilimanjaro mountain porters to community members. | DCE | Adults at risk of HIV | Yes | 621 | FG, KII | 5 | 9 |
| Ostermann [ | Tanzania | 2012–13 | To evaluate factors that influence HIV-testing preferences. | DCE | Adults at risk of HIV | Yes | 486 | FG, KII, LR, pilot survey | 5 | 9 |
| Bristow [ | Haiti | 2014 | To identify factors associated with willingness to test for HIV and syphilis. | CA | Adults without HIV | n/s | 298 | LR | 6 | 8 |
| Strauss [ | Kenya | 2015 | To identify preferences for HIV testing service delivery models. | DCE | Male truck drivers without HIV | Yes | 305 | n/s | 6 | 8 |
| Strauss [ | South Africa | 2016 | To examine preferences for HIV counselling and testing service package characteristics. | DCE | Adolescents | No | 248 | FG, LR | 7 | 16 |
| Zanolini [ | Zambia | 2017 | To assess the attitudes and preferences for HIV self-testing. | DCE | Adolescents and adults without HIV | Yes | 1,617 | KII | 3 | 9 |
| Indravudh [ | Malawi, Zimbabwe | 2017 | To identify preferences for HIV self-testing delivery characteristics. | DCE | Adolescents and youth without HIV | Yes | 138 | FG, KII, LR | 6 | 6 |
| Albus [ | Germany | 2001 | To explore preferences regarding medical and psychosocial support to increase ART adherence. | CA | PLWH | No | 231 | KII | 9 | 9 |
| Opuni [ | South Africa | 2006 | To measure preferences for ART clinics characteristics. | DCE | PLWH | No | 1,287 | FG, KII, LR | 4 | 20 |
| Baltussen [ | Ghana | 2006 | To determine the relative importance of different criteria in identifying priority interventions for HIV and other diseases in Ghana. | DCE | Policy makers | No | 30 | KII, LR | 6 | 12 |
| Youngkong [ | Thailand | 2010 | To determine preferences on the relative importance of criteria for priority setting of HIV programmes in Thailand. | DCE | Policy makers, PLWH, adults without HIV | No | 74 | FG | 3 | 16 |
| Michaels-Igbokwe [ | Malawi | 2012 | To examine preferences for integrated family planning and HIV services. | DCE | Adolescents | Yes | 524 | FG, KII, LR | 6 | 12 |
| Kruk [ | Ethiopia, Mozambique | 2014 | To identify preferences for attributes of outpatient visits for ART in the context of lifelong care. | DCE | Women with HIV | Yes | 2,090 | FG, KII, LR | 6 | 8 |
| Miners [ | United Kingdom | 2014–15 | To understand which aspects of general practitioner and HIV clinic appointments PLWH most value when seeking advice for new health problems. | DCE | PLWH | No | 1,106 | FG, LR | 7 | 12 |
| Kennedy [ | Canada | 2015 | To evaluate pregnancy-planning choices. | DCE | PLWH and people affected by HIV | n/s | 25 | n/s | 5 | n/s |
| Jones [ | USA | 2016 | To explore the importance of attributes involved in reproductive decision-making. | CA | Women with HIV | n/s | 49 | KII | 5 | 12 |
| Safarnejad [ | Vietnam | 2017 | To elicit preferences and trade-offs made between different HIV programs by relevant stakeholders and decision-makers. | DCE | Policy makers | No | 69 | KII, LR | 5 | 8 |
| Stone [ | USA | 2002 | To assess PLWH perceptions of the impact on adherence of various attributes of ART and to compare ART regimens based on patients’ perceptions of their likelihood to promote adherence. | CA | PLWH | n/s | 299 | n/s | 10 | 21 |
| Sherer [ | USA | 2005 | To assess patient preferences toward ART regimen attributes. | DCE | PLWH | No | 387 | n/s | 9 | 5 |
| Hauber [ | USA | 2006–07 | To estimate the relative importance of short-term and long-term adverse event risks in exchange for virologic suppression. | DCE | PLWH | No | 147 | FG, KII, pilot survey | 5 | 24 |
| Beusterien [ | Germany, USA | 2007 | To examine preferences for ART attributes. | DCE | PLWH | No | 288 | LR | 13 | 8 |
| Muhlbacher [ | Germany | 2009–10 | To examine patient preferences for HIV treatment including effectiveness, quality of life, and further treatment options. | DCE | PLWH | No | 218 | LR | 6 | 8 |
| Muhlbacher [ | Germany | 2010 | To compare patient and physician perspectives of aspects of HIV treatment quality such as effectiveness, quality of life and further treatment options. | DCE | Physicians | No | 131 | LR | 6 | 8 |
| Lloyd [ | United Kingdom | 2013 | To elicit patient and physician preferences for ART. | CA | PLWH and physicians | n/s | 325 | KII, LR | 8 | n/s |
| Bregigeon-Ronot [ | France | 2014 | To elicit preferences for attributes of ART. | DCE | PLWH | No | 101 | KII | 7 | 19 |
| Orme [ | United Kingdom | 2014 | To estimate the strength of patient preferences for simplified ART regimens. | DCE | PLWH | No | 278 | KII | 4 | 12 |
| Gazzard [ | France, Germany, Spain, Italy, United Kingdom | 2014 | To examine preferences for ART characteristics. | DCE | PLWH | n/s | 1,582 | KII, LR | 7 | n/s |
| Bayoumi [ | Canada | 2015 | To elicit preferences about the relative importance of various attributes of ART. | DCE | PLWH | n/s | 127 | n/s | 6 | 16 |
| Hendriks [ | Colombia | 2016 | To rank patients’ preferred characteristics of ART. | BWS | PLWH | No | 283 | LR | 5 | 16 |
ART, antiretroviral therapy; AT, acceptability trial; CA, conjoint analysis; DCE, discrete choice experiment; KII, key informant interview; LR, literature review; MSM, men who have sex with men; n/s, not specified; PLWH, people living with HIV; PrEP, pre-exposure prophylaxis; USA, United States of America
* Indicates year of publication when the year(s) the study was conducted were not reported.
† Indicates conference abstract.
Characteristics of included studies (n = 57).
| Characteristic | n (%) |
|---|---|
| Study type | |
| Discrete choice experiment | 36 (63%) |
| Conjoint analysis | 21 (37%) |
| Best-worst scaling | 2 (4%) |
| Region | |
| North America | 16 (28%) |
| South America and Caribbean | 4 (7%) |
| Europe | 14 (25%) |
| Asia | 7 (12%) |
| Africa | 17 (30%) |
| Participants | |
| People living with HIV | 20 (35%) |
| People without HIV | 26 (46%) |
| Female sex workers | 4 (7%) |
| Men who have sex with men | 8 (14%) |
| Transgender women | 3 (5%) |
| Healthcare workers | 3 (5%) |
| Policy makers | 3 (5%) |
| Probability sampling | |
| Yes | 11 (19%) |
| No | 37 (65%) |
| Not specified | 9 (16%) |
| Sample size, median (IQR) | 288 (138–496) |
| Sample size | |
| < 100 | 9 (16%) |
| 100–250 | 15 (26%) |
| 251–500 | 19 (33%) |
| > 500 | 14 (25%) |
| Attribute and level determination | |
| Literature review | 33 (58%) |
| Key informant interviews | 35 (61%) |
| Focus groups | 27 (47%) |
| Other | 7 (12%) |
| Not specified | 6 (11%) |
| Attributes, mean (range) | 6 (3–13) |
| Choice sets, mean (range), n = 52 | 12 (5–49) |
a Percentages exceed 100% because some studies were conducted in > 1 field.
b Includes adolescents, adults, members of serodiscordant couples, and male truck drivers.
c Includes acceptability trial (n = 4) and pilot survey (n = 3).
Fig 4Frequency of stated-preference studies published during three-year periods from 2000 to 2017.
Critical appraisal of full-text articles (n = 51).
| Characteristic | n (%) |
|---|---|
| Methodology reported was concordant | |
| Yes | 41 (80%) |
| No | 10 (20%) |
| Eligibility criteria was explicit | |
| Yes | 35 (69%) |
| No | 16 (31%) |
| Sample size justification, power description or variance and effect estimates provided | |
| Yes | 5 (10%) |
| No | 46 (90%) |
| Factorial design | |
| Full factorial | 6 (12%) |
| Fractional factorial | 45 (88%) |
| Forced choice used | |
| Yes | 5 (10%) |
| No | 13 (25%) |
| Not specified | 33 (65%) |
| Method of profile generation and allocation to choice sets specified | |
| Yes | 21 (41%) |
| No | 30 (59%) |
| Method of data collection | |
| Face-to-face interviews | 37 (73%) |
| Web surveys | 8 (16%) |
| Self-administered questionnaires | 6 (12%) |
| Phone interviews | 1 (2%) |
| Participation rate ≥ 50% | |
| Yes | 22 (43%) |
| No | 1 (2%) |
| Not specified | 28 (55%) |
| Understanding and complexity checked | |
| Yes | 24 (47%) |
| No or not specified | 27 (53%) |
| Participants randomly allocated to versions | |
| Yes | 21 (41%) |
| No or not specified | 30 (59%) |
a Percentages exceed 100% because some studies used >1 data collection method.